Matinas BioPharma Holdings, Inc. filed a Form 8-K on November 3, 2026, disclosing the termination of an agreement with a former financial advisor and a cash settlement payment of $562,500.

Key Highlights

  • Agreement terminated: Matinas BioPharma and a former financial advisor terminated their agreement on November 3, 2026.
  • Original agreement terms: The agreement provided for payment of up to $2.0 million in cash and up to $2.0 million in stock tied to the closing of certain business combinations.
  • Settlement payment: In connection with the termination, the company paid the advisor $562,500 in cash.
  • Mutual releases: The company and the advisor exchanged mutual releases, subject to certain contingencies.
  • Exchange listing: Common stock is listed on NYSE American under the symbol MTNB (NYSE American:MTNB).

Matinas BioPharma Terminates Financial Advisor Agreement and Settles for $562,500

According to the filing, Matinas BioPharma Holdings, Inc. and a former financial advisor to the company terminated their agreement on November 3, 2026. The company disclosed that the original agreement had provided for, "among other things, the payment to the Advisor of up to $2.0 million in cash and up to $2.0 million in stock in connection with the closing of certain business combinations."

In connection with the termination, the filing states that the company paid the advisor $562,500 in cash. As part of the settlement, the company and the advisor "exchanged mutual releases, subject to certain contingencies," according to the filing. The company did not identify the former financial advisor by name in the disclosure.

The filing was signed by Jerome D. Jabbour, Chief Executive Officer of Matinas BioPharma Holdings, Inc., and was submitted under Item 8.01 (Other Events) of Form 8-K. The company is incorporated in Delaware and is headquartered at 1545 Route 206 South, Suite 302, Bedminster, New Jersey 07921.

What Was Disclosed

Matinas BioPharma disclosed the November 3, 2026, termination of an agreement with a former financial advisor, the payment of $562,500 in cash to that advisor, and the exchange of mutual releases subject to certain contingencies.